3:36 PM ยท 27 January 2025

Massive sell-off in Allakos shares following disappointing clinical trial results for AK006 ๐Ÿ“‰

Allakos (ALLK.US) is down more than 77% today after releasing disappointing results from clinical trials of its drug AK006. The drug was intended to treat Chronic Spontaneous Urticaria (CSU), but the phase 1 trial results did not demonstrate sufficient therapeutic activity. As a result, the company has decided to abandon the project, which was one of its leading programs. Following the discontinuation of the project, the company announced it will lay off 75% of its workforce and will begin a review of available strategies to find a new alternative for its future operations.

 

Source: xStation

30 October 2026, 2:16 PM

US OPEN: Bloody end to the quarter. Intel loses nearly 1/3 of its value, and the crypto market shakes off a hack on the largest exchange.

30 October 2026, 11:08 AM

Market Wrap: Binance Hack Shakes Markets. European Equities Under Pressure

30 October 2026, 9:27 AM

Intel has come face to face with reality. A Turnaround is still a long way off.

29 October 2026, 10:25 PM

Amazon: Record-breaking operating margin outshined by capex growth

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissรฃo de Valores Mobiliรกrios (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits